CHEK2*1100delC heterozygosity predicts increased risk of breast cancer and poor outcome
This article has no abstract so we have provided the first paragraph of the full text.
The checkpoint kinase CHEK2 acts to block cell proliferation and to initiate repair after DNA damage; dysfunction of the CHEK2 gene can lead to loss of these key functions and possible susceptibility to cancer. A deletion mutation (CHEK2*1100delC) has previously been linked to increased risk of developing breast, prostate and colorectal cancers. Two recent papers, both published in the Journal of Clinical Oncology, have discussed CHEK2*1100delC heterozygosity in cancer, with a particular focus on breast cancer.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.